Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxytriphenylmethane SCHEMBL9103 | 0.70 | MAPK1 (0.48) | MAPK1KCNN4ALDH1A1ALOX15CES1 | |
| SCHEMBL9439627 | 0.70 | KCNN4 (0.42) | MAPK1KCNN4ALDH1A1ALOX15TSHR | |
| SCHEMBL3282883 | 0.69 | KCNN4 (0.45) | MAPK1KCNN4ALDH1A1ALOX15TSHR | |
| Methoxytriphenylmethane SCHEMBL27882817 | 0.69 | MAPK1 (0.46) | MAPK1KCNN4ALDH1A1ALOX15CES1 | |
| SCHEMBL3022980 | 0.67 | MAPK1 (0.50) | MAPK1KCNN4ALDH1A1ALOX15CES1 | |
| SCHEMBL5079101 | 0.65 | KCNN4 (0.41) | MAPK1KCNN4ALDH1A1ALOX15TSHR | |
| SCHEMBL1659349 | 0.65 | MAPK1 (0.48) | MAPK1KCNN4ALDH1A1ALOX15CES1 | |
| SCHEMBL1264373 | 0.65 | MAPK1 (0.48) | MAPK1KCNN4ALDH1A1ALOX15CES1 | |
| SCHEMBL3447538 | 0.65 | MAPK1 (0.48) | MAPK1KCNN4ALDH1A1ALOX15TSHR | |
| SCHEMBL3227998 | 0.65 | KCNN4 (0.48) | MAPK1KCNN4ALDH1A1TSHRKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | claimed |
| WO-2021119325-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021119325-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210071181-A1 | PHARMACEUTICAL COMPOSITION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3502255-A1 | PHARMACEUTICAL COMPOSITION | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-26 | — | — | EP | disclosed |
| US-20190071672-A1 | Pharmaceutical Composition | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-03-07 | — | — | US | disclosed |
| EP-3431602-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-01-23 | — | — | EP | disclosed |
| EP-2666859-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-01-02 | — | — | EP | disclosed |
| US-20180195062-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| CN-103384681-B | Binding agents | 霍夫曼-拉罗奇有限公司 | 2018-05-18 | — | — | CN | disclosed |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | ENZON PHARMACEUTICALS, INC | 2005-01-20 | — | — | US | disclosed |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | SANTARIS PHARMA A/S | 2004-12-09 | — | — | US | disclosed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | disclosed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2003085110-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | SANTARIS PHARMA A/S (DK) | 2003-10-16 | — | — | WO | disclosed |
| WO-1996030383-A1 | NUCLEIC ACID POLYESTER POLYAMIDES | NOE CHRISTIAN (AT) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | HRAS, KRAS, NRAS | MAPK1 1990/4885KCNN4 3488/4885ALDH1A1 4561/4885 |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | TXN, TXN2, TXNRD3 | MAPK1 3958/4885KCNN4 3391/4885ALDH1A1 4582/4885 |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | HIF1AN, HIF1A, HYOU1 | MAPK1 2284/4885KCNN4 4537/4885ALDH1A1 2340/4885 |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | BIRC5, XIAP, BIRC3 | MAPK1 4632/4885KCNN4 3195/4885ALDH1A1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.